Real-world study tracks ribociclib in elderly breast cancer patients
NCT ID NCT06625333
First seen Feb 23, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study watches 329 older patients (65+) with HR+/HER2- advanced breast cancer who are already taking ribociclib with hormone therapy. Researchers track quality of life, treatment success, and side effects over 12 months in everyday medical practice. The goal is to learn how well this treatment works for older adults in real life, not in a controlled lab setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Arkhangelsk, 163045, Russia
-
Novartis Investigative Site
Barnaul, 656045, Russia
-
Novartis Investigative Site
Bryansk, 241028, Russia
-
Novartis Investigative Site
Chelyabinsk, 454080, Russia
-
Novartis Investigative Site
Irkutsk, 664035, Russia
-
Novartis Investigative Site
Kemerovo, 650036, Russia
-
Novartis Investigative Site
Khabarovsk, 680042, Russia
-
Novartis Investigative Site
Khanty-Mansiysk, 628012, Russia
-
Novartis Investigative Site
Kirov, 610021, Russia
-
Novartis Investigative Site
Krasnoyarsk, 660022, Russia
-
Novartis Investigative Site
Obninsk, 249036, Russia
-
Novartis Investigative Site
Perm, 614066, Russia
-
Novartis Investigative Site
Rostov-on-Don, 344006, Russia
-
Novartis Investigative Site
Saint Petersburg, 194291, Russia
-
Novartis Investigative Site
Saint Petersburg, 197758, Russia
-
Novartis Investigative Site
Tambov, 392000, Russia
-
Novartis Investigative Site
Tver', 170008, Russia
-
Novartis Investigative Site
Ufa, 450054, Russia
-
Novartis Investigative Site
Yaroslavl, 150054, Russia
-
Novartis Investigative Site
Yekaterinburg, 620036, Russia
Conditions
Explore the condition pages connected to this study.